A mutation in the Kirsten rat sarcoma virus transforming protein (KRAS) is the most common genomic driver identified in patients with lung adenocarcinoma. It is a key component of the PI3K and MAPK pathways and is an important regulator of cell proliferation and survival. Tobacco use and ...
Haratani K, Hayashi H, Tanaka T, et al. Tumor immune microenvironment and nivolumab efficacy in EGFR mutation-positive non-small-cell lung cancer based on T790M status after disease progression during EGFR-TKI treatment. ...
[3] Jänne PA, Riely GJ, Gadgeel SM, et al. Adagrasib in Non-Small-Cell Lung Cancer Harboring a KRAS(G12C) Mutation. N Engl J Med. 2022. 387(2): 120-131. [4] Skoulidis F, Li BT, Dy GK, et al. Sotorasib for Lung Cancers with KRAS p.G12C Mutation. N Engl J Med....
Finally, we aimed to replicate these findings in vitro using isogenic cell lines and mCRC patient-derived organoids (PDOs) (n = 7; Supplementary Table9).KRASG12mutation knock in significantly reduced responsiveness to FTD (the cytotoxic component of FTD/TPI) in two colorectal cancer cell ...
(negative < 1%; positive > = 1%), (b)KRASmutation status with survival in stage III unresected NSCLC patients diagnosed 2000–2013 with follow-up through 2014, and registered in the Danish Lung Cancer Group Registry. (NSCLC: non-small cell lung cancer; PD-L1: programmed ...
The KRAS mutation remains the most common driver mutation in patients with non-small cell lung cancer (NSCLC) and confers a poor prognosis. Thus far, efforts to target this mutation over the last two decades have been unsuccessful. Over the past 5 y
转移性结直肠癌(metastatic colorectal cancer,mCRC)患者的5年总生存(overall survival,OS)率不足15%,治疗方法主要以化疗和靶向治疗为主[1],然而很多结直肠癌(colorectal cancer,CRC)患者发展到晚期阶段已无法耐受高强度的化疗,这种情况下结直肠癌的精准治...
PDL-1 lived longer when treated with immunotherapy alone, compared to patients without this mutation. This survival difference by KRAS status was not seen, however, in patients treated with both chemotherapy and immunotherapy, suggestingcombination therapyfor patients without the mutation may be ...
The KRAS mutation remains the most common driver mutation in patients with non-small cell lung cancer (NSCLC) and confers a poor prognosis. Thus far, efforts to target this mutation over the last two decades have been unsuccessful. Over the past 5 years, many efforts to develop drugs that ...
Sotorasib for Lung Cancers with KRAS Mutation 2021年6月24日 朗读者:Dr. Stephen Morrissey,NEJM常务执行主编 非小细胞肺癌治疗领域近年来的进展使患者死亡率大幅下降。然而,在接受二线或后续治疗的晚期NSCLC患者中,经过化疗或检查点抑制剂治疗后,只有6%~...